Atreca, Inc. (BCEL)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
At close: 03:59PM EDT
| Previous Close | 0.0920 |
| Open | 0.0980 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0920 - 0.0980 |
| 52 Week Range | 0.0520 - 1.2640 |
| Volume | |
| Avg. Volume | 417,154 |
| Market Cap | 3.648M |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%
Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.
- Simply Wall St.
We're A Little Worried About Atreca's (NASDAQ:BCEL) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
© 2024 Yahoo. All rights reserved.